Patients With Gynecologic Cancer Who Were Carriers For A BRCA1/2 Pathogenic Variant And Received RRS Experienced Improved Menopause-Related Quality Of Life Compared With Those Who Received RRSO, Study Finds

Cancer Network (9/14, Pelosci) reported, “Patients with gynecologic cancer who were carriers for a BRCA1/2 pathogenic variant and received risk-reducing salpingectomy (RRS) experienced improved menopause-related quality of life compared with those who received risk-reducing salpingo-oophorectomy (RRSO), regardless of treatment with hormone replacement therapy, according to findings from a study.” The research was published in JAMA Oncology.